Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device

The purpose of this research study is to evaluate a new method of T cell depletion using the
Miltenyi CliniMACS™ device for patients undergoing a peripheral stem cell transplant
utilizing either a unrelated donor or partially matched/haploidentical related donor. This
new method is called α/β (alpha/beta) T cell depletion and CD19+ B cell depletion. This pilot
study will evaluate if this new method of T cell and B cell depletion is a more effective way
of removing T cells thus reducing the risk of severe acute and chronic GVHD and result in a
durable engraftment.

Inclusion Criteria:

Patient:

1. Age. Patient age < 23 years. Both genders and all races eligible.

2. Disease eligibility

Leukemias/lymphomas:

- Acute myeloid leukemia, primary or secondary

- Disease status: remission or <10% bone marrow blasts

- Myelodysplasia

- Acute lymphoblastic leukemia

- Disease status: in hematologic remission

- Chronic myelogenous leukemia:

- Disease status: chronic phase, accelerated phase or blast crisis now in second chronic
phase.

- Mixed lineage or biphenotypic acute leukemia

- Lymphoblastic lymphoma

- Disease status: remission

- Burkitt's lymphoma/leukemia:

- Disease status: in remission

Exclusion Criteria:

- Patient

1. Patients who do not meet disease, organ or infectious criteria.

2. No suitable donor